Table 4.

Outcomes and treatment effect in patients with a heart rate ≥ 77 b.p.m. at rest

	Outcomes, % (n)		Treatment effect of ivabradine vs. placebo
	Ivabradine (n = 1657)	Placebo (n = 1700)	NNT	HR	95% CI	P
CV mortality or hospitalization for worsening HF	27.4% (n = 454)	34.1% (n = 581)	17	0.75	0.67–0.85	<0.0001
CV hospitalization	32.2% (n = 534)	38.0% (n = 647)	18	0.79	0.71–0.89	<0.0001
CV mortality	15.3% (n = 255)	18.3% (n = 312)	64	0.81	0.69–0.96	0.0137
Hospitalization for worsening HF	17.9% (n = 298)	24.5% (n = 418)	18	0.69	0.59–0.80	<0.0001
HF death	4.0% (n = 67)	6.2% (n = 107)	94	0.61	0.45–0.83	0.0017
All‐cause hospitalization	40.2% (n = 667)	45.7% (n = 778)	17	0.82	0.74–0.91	0.0002
All‐cause mortality	17.2% (n = 285)	20.5% (n = 350)	56	0.81	0.69–0.94	0.0074

CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; NNT, number needed to be treated to prevent pre‐specified outcomes within 1 year.